Cited by 313Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose

Open access

Keech, Anthony, Colquhoun, David, Best, James, Kirby, Adrienne, Simes, R. John, Hunt, David, Hague, Wendy, Beller, Elaine, Arulchelvam, Manjula, Baker, Jennifer, Tonkin, Andrew, for the LIPID Study Group·2003·Diabetes Care

DOI 10.2337/diacare.26.10.2713

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE—Diabetes, a major health problem worldwide, increases the risk of cardiovascular disease and its associated mortality. Evidence of the overall benefits of lipid modification in this area is needed. RESEARCH DESIGN AND METHODS—The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that cholesterol-lowering treatment with pravastatin reduced mortality and coronary heart disease (CHD) events in 9,014 patients aged 31–75 years with CHD and total cholesterol 4.0–7.0 mmol/l. We measured the effects of pravastatin therapy, 40 mg/day over 6.0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG). RESULTS—In patients allocated to placebo, the risk of a major CHD event was 61% higher in patients with diabetes and 23% higher in the IFG group than in patients with normal fasting glucose, and the risk of any cardiovascular event was 37% higher in the diabetic group and 19% higher in the IFG group. Pravastatin therapy reduced the risk of a major CHD event overall from 15.9 to 12.3% (relative risk reduction [RRR] 24%, P < 0.001) and from 23.4 to 19.6% in the diabetic group (19%, P = 0.11); in the diabetic group, the reduction was not significantly different from the reductions in the other groups. Pravastatin reduced the risk of any cardiovascular event from 52.7 to 45.2% (21%, P < 0.008) in patients with diabetes and from 45.7 to 37.1% (26%, P = 0.003) in the IFG group. Pravastatin reduced the risk of stroke from 9.9 to 6.3% in the diabetic group (RRR 39%, CI 7–61%, P = 0.02) and from 5.4 to 3.4% in the IFG group (RRR 42%, CI −9 to 69%, P = 0.09). Pravastatin did not reduce the incidence of diabetes. Over 6 years, pravastatin therapy prevented one major CHD event (CHD death or nonfatal myocardial infarction) in 23 patients with IFG and 18 patients with diabetes. A meta-analysis of other major trials confirmed the high absolute risks of diabetes and IFG and the absolute benefits of statin therapy in these patients. CONCLUSIONS—Cholesterol-lowering treatment with pravastatin therapy prevents cardiovascular events, including stroke, in patients with diabetes or IFG and established CHD.

Integrity signals

Registry

Crossref · 10.2337/diacare.26.10.2713

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H. O. M., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,294

Show all 36 references

Sorted by citations

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Diabetes and Vascular Disease
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,675
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,455
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L. J., Banka, C. L., Benjamin, E. J., Berra, K. A., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 753
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L. J., Banka, C. L., Benjamin, E. J., Berra, K. A., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 582
Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies
Gerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., Yazdi, H., & Booker, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.05.004 · Cited by 575
Self-citation
Endothelial dysfunction in diabetes mellitus.
Hadi, H. A. R., & Suwaidi, J. M. S. A. (2007) · Europe PMC (PubMed Central) · Cited by 568
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Vascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 432
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus
Navarese, E. P., Buffon, A., Andreotti, F., Koziński, M., Welton, N. J., Fabiszak, T., Caputo, S., Grześk, G., Kubica, A., Świątkiewicz, I., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.037 · Cited by 315
Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus
Alshehry, Z. H., Mundra, P. A., Barlow, C. K., Mellett, N. A., Wong, G., McConville, M. J., Simes, J. R., Tonkin, A., SULLIVAN, D. R., Barnes, E. H., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.023233 · Cited by 270
Self-citation
The prevention of type 2 diabetes
F. T. D. P. P. R. G., Crandall, J. P., Knowler, W. C., Kahn, S. E., Marrero, D., Florez, J. C., Bray, G. A., Haffner, S. M., Hoskin, M., & Nathan, D. M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0843 · Cited by 261
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Cramer, C., Haan, M. N., Galea, S., Langa, K. M., & Kalbfleisch, J. D. (2008) · Neurology · doi:10.1212/01.wnl.0000319647.15752.7b · Cited by 255
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes
Howard, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 238
Diabetic Dyslipidemia
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
Insulin resistance and the endothelium
Hsueh, W. A., Lyon, C. J., & Quiñones, M. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.042 · Cited by 236
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients
Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., & Shin, E. K. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.053 · Cited by 229
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 235
Pathophysiology of dyslipidaemia in the metabolic syndrome
Kolovou, G. D., Anagnostopoulou, K. K., & Cokkinos, D. V. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.025601 · Cited by 223
Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Calkin, A. C., Drew, B. G., Ono, A., Duffy, S. J., Gordon, M. V., Schoenwaelder, S. M., Sviridov, D., Cooper, M. E., Kingwell, B. A., & Jackson, S. P. (2009) · Circulation · doi:10.1161/circulationaha.109.870709 · Cited by 198
Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.
Santaguida, P. L., Balion, C. M., Hunt, D., Morrison, K. M., Gerstein, H. C., Raina, P. S., Booker, L., & Yazdi, H. (2005) · PubMed Central · Cited by 195
Self-citation
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms
Chruściel, P., Sahebkar, A., Rembek, M., Șerban, M.-C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Moșteoru, S., Blaha, M. J., Martin, S. S., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.897 · Cited by 195
Statin Therapy in the Prevention of Recurrent Cardiovascular Events
Gutierrez, J., Ramı́rez, G., Rundek, T., & Sacco, R. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2145 · Cited by 186
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.03.001 · Cited by 179
Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus
Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169
A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
Padwal, R. S., Majumdar, S. R., Johnson, J. A., Varney, J., & McAlister, F. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.736 · Cited by 164
Prevenção do diabetes mellitus tipo 2
Lyra, R., de Oliveira, M., Lins, D. D. C., & Cavalcanti, N. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200010 · Cited by 164
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
Self-citation
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg, H. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2084 · Cited by 146
Statin use and the risk of developing diabetes: a network meta‐analysis
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4020 · Cited by 147
Diabetes mellitus and stroke
IDRIS, I. R., Thomson, G., & Sharma, J. C. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00682.x · Cited by 133
Metabolic Syndrome and Insulin Resistance
Bagry, H., Raghavendran, S., Carli, F., Warner, D. S., & Warner, M. A. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181649314 · Cited by 132
Differential metabolic effects of distinct statins
Koh, K. K., Sakuma, I., & Quon, M. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.036 · Cited by 130
Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)
Oikawa, S., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Sasaki, J., Hishida, H., Itakura, H., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.029 · Cited by 125
Stroke in patients with diabetes mellitus
Mankovsky, B., & Ziegler, D. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.490 · Cited by 123
Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes
Vallejo‐Vaz, A. J., Seshasai, S. R. K., Kurogi, K., Michishita, I., Nozue, T., Sugiyama, S., Tsimikas, S., Yoshida, H., & Ray, K. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.001 · Cited by 124
Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys
Groups*, T. E. I. A. I., Pyörälà, K., Lehto, S., Bacquer, D. D., SUTTER, J. D., Sans, S., Keil, U., Wood, D., & Backer, G. D. (2004) · Diabetologia · doi:10.1007/s00125-004-1438-z · Cited by 118
Diabetes in Older People
Meneilly, G. S., Knip, A., Miller, D. B., Sherifali, D., Tessier, D., & Zahedi, A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.021 · Cited by 120
A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
Jani, R. H., Pai, V., Jha, P. R., Jariwala, G., Mukhopadhyay, S., Bhansali, A. K., & Joshi, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0253 · Cited by 120
Are statins diabetogenic?
Sampson, U. K. A., Linton, M. F., & Fazio, S. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283470359 · Cited by 118
Statins and the risk of new-onset diabetes
Preiss, D., & Sattar, N. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 113
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention
Zhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 109
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
The FIELD Study Investigators (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-13 · Cited by 103
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
The FIELD Study Investigators (2004) · Cardiovascular Diabetology · doi:10.1186/1475-2840-3-9 · Cited by 101
The metabolic syndrome
Sarti, C., & Gallagher, J. C. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.06.014 · Cited by 98
Statin induced diabetes and its clinical implications
Aiman, U., Najmi, A., & Khan, R. A. (2014) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.136097 · Cited by 93
The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials
Coleman, C. I., Reinhart, K. M., Kluger, J., & White, C. M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x292029 · Cited by 90
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Undertreatment of cardiovascular risk factors among persons with diabetes in the United States
Malik, S., López, V. A. Q., Chen, R. K., Wu, W., & Wong, N. D. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.10.016 · Cited by 85
Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes
Neves, J. S., Newman, C. B., Bostrom, J., Buysschaert, M., Newman, J. D., Medina, J. L., Goldberg, I. J., & Bergman, M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109980 · Cited by 88
Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus
Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83
Lipid Management in Type 2 Diabetes
Solano, M. P., & Goldberg, R. B. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.27 · Cited by 82
Diabetes in the Elderly
Meneilly, G. S., Knip, A., & Tessier, D. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.045 · Cited by 83
Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival
Wang, C. C. L., & Reusch, J. E. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.036 · Cited by 78
Management of Dyslipidemia in Diabetes
Solano, M. P., & Goldberg, R. B. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000188034.76283.5e · Cited by 79
Benefits of statin therapy and compliance in high risk cardiovascular patients
DEEDWANIA, P. C., & Lardizabal (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9474 · Cited by 75
Statin use and risk of diabetes mellitus
Chogtu, B. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.352 · Cited by 80
Dyslipidemia in type 2 diabetes mellitus
Gadi, R., & Samaha, F. F. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0036-0 · Cited by 78
Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis
Sheng, Z., Cao, J., Pang, Y.-C., Xu, H., Chen, J., Yuan, J., Wang, R., Zhang, C., Wang, L., & Dong, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00455 · Cited by 85
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 80
Hyperglycemia, Lipoprotein Glycation, and Vascular Disease
Veiraiah, A. (2005) · Angiology · doi:10.1177/000331970505600411 · Cited by 74
Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol
Su, X., Kong, Y., & Peng, D. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1080-x · Cited by 72
Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
Berne, C., Siewert-Delle, A., & the URANUS study investigators (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-7 · Cited by 73
Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome
Bulc??o, C., Ribeiro‐Filho, F. F., Sañudo, A., & Ferreira, S. G. R. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707030-00007 · Cited by 71
Risk Constellations in Patients with the Metabolic Syndrome: Epidemiology, Diagnosis, and Treatment Patterns
Haffner, S. M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.008 · Cited by 70
Glucose challenge test screening for prediabetes and undiagnosed diabetes
Phillips, L. S., Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Chatterjee, R., Narayan, K. M. V., & Koch, D. D. (2009) · Diabetologia · doi:10.1007/s00125-009-1407-7 · Cited by 67
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch, M. E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00780306 · Cited by 62
Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis
Wang, S., Cai, R., Yuan, Y., Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2017) · Scientific Reports · doi:10.1038/srep39982 · Cited by 72
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation
Calkin, A. C., Giunti, S., Sheehy, K., Chew, C., Boolell, V., Rajaram, Y. S., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2008) · Diabetologia · doi:10.1007/s00125-008-1060-6 · Cited by 63
Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification
Wong, K., Glovaci, D., Malik, S., Franklin, S. S., Wygant, G. D., Iloeje, U. H., Kan, H., & Wong, N. D. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.006 · Cited by 62
Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis
Alvarez-Jimenez, L., Morales-Palomo, F., Moreno-Cabañas, A., Ortega, J. F., & Mora-Rodríguez, R. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175672 · Cited by 60
A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design
Preiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 60
Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Vignini, A., Giulietti, A., Nanetti, L., Raffaelli, F., Giusti, L., Mazzanti, L., & Provinciali, L. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309030003 · Cited by 57
Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis
de Vries, F. M., Kolthof, J., Postma, M. J., Denig, P., & Hak, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111247 · Cited by 56
Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose
Kostapanos, M. S., Milionis, H. J., Agouridis, A. P., Rizos, C. V., & Elisaf, M. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02101.x · Cited by 54
Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis
Tkáč, I. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.002 · Cited by 54
Stroke in Patients With Diabetes and Hypertension
McFarlane, S. I., Sica, D. A., & Sowers, J. R. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04379.x · Cited by 53
Effects of High-Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Nonobese Type 2 Diabetic Patients
Szendroedi, J., Anderwald, C. H., Krššák, M., Bayerle‐Eder, M., Esterbauer, H., Pfeiler, G., Brehm, A., Nowotny, P., Hofer, A., Waldhäusl, W. K., et al. (2008) · Diabetes Care · doi:10.2337/dc08-1123 · Cited by 53
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
Sander, D., & Kearney, M. T. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5143-1 · Cited by 52
Statin therapy and related risk of new-onset type 2 diabetes mellitus
Ruscica, M., Macchi, C., Morlotti, B., Sirtori, C. R., & Magni, P. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.003 · Cited by 52
Diabetes and Cardiovascular Disease Prevention in Older Adults
Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50
Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: Diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study
Tajima, N., Kurata, H., Nakaya, N., Mizuno, K., Ohashi, Y., Kushiro, T., Teramoto, T., Uchiyama, S., & Nakamura, H. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.027 · Cited by 50
Management of Diabetic Dyslipidemia
Solano, M. D. P., & Goldberg, R. B. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.001 · Cited by 47
Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: Evidence for statin-induced hepatic insulin sensitization
Naples, M., Federico, L. M., Xu, E., Nelken, J., & Adeli, K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.003 · Cited by 49
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
Daskalopoulou, S. S., & Mikhailidis, D. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89856 · Cited by 48
Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease
Lardizabal, J. A., & DEEDWANIA, P. C. (2011) · Cardiology Clinics · doi:10.1016/j.ccl.2010.10.002 · Cited by 46
Lipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 48
Type III Allergy to Insulin Detemir
Darmon, P., Castera, V., Koeppel, M.-C., Petitjean, C., & Dutour, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2980 · Cited by 47
Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress
Tian, X., Wong, W. T., Xu, A., Chen, Z., Lu, Y., Lm, L., Lee, V. W. Y., Lau, C., Yao, X., & Huang, Y. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01416.x · Cited by 46

Authors: Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., Tonkin, A., & for the LIPID Study Group
Affiliations: The University of Sydney (AU)
Wesley Hospital (AU)
St Vincent's Hospital Melbourne (AU)
The Royal Melbourne Hospital (AU)
National Heart Foundation of Australia (AU)
ORCID: Keech, Anthony
Best, James
Kirby, Adrienne
Simes, R. John
Hunt, David
Beller, Elaine
Tonkin, Andrew
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2003-10-01
Volume: 26
Issue: 10
Pages: 2713-2721
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.26.10.2713
OpenAlex: W2086139919
Cited by: 313
References: 36
Citations by year: 2026: 4 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 11 · 2018: 7 · 2017: 6 · 2016: 11 · 2015: 13 · 2014: 14 · 2013: 21 · 2012: 14
FWCI: 26.36
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Griffith Research Online (submittedVersion)
Funders: Bristol-Myers Squibb
National Heart Foundation of Australia
Medical Research Council
National Health and Medical Research Council
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, secondary prevention, cardiovascular events, diabetes mellitus, impaired fasting glucose, coronary artery disease, myocardial infarction, stroke, LIPID trial, cholesterol-lowering therapy, statins, cardiovascular risk reduction, hypercholesterolemia, diabetes incidence, nonfatal myocardial infarction, cardiovascular hospitalization
MeSH terms: Adult, Aged, Angina, Unstable, Anticholesteremic Agents, Blood Glucose, Cardiovascular Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 2, Fasting, Female, Follow-Up Studies, Humans, Hyperlipidemias, Male, Middle Aged, Myocardial Infarction, Risk Factors, Treatment Outcome, Pravastatin, Glucose Intolerance, Stroke, Coronary Restenosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks